Ratio Therapeutics
Series BNext-generation targeted radiopharmaceuticals and precision oncology therapeutics
BiopharmaTotal Raised: $70M👥 51-200 Employees📍 Boston, USA
About Ratio Therapeutics
Ratio Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapies for cancer patients. Using proprietary Trillium and Macoria discovery platforms, Ratio designs radiolabeled small molecules with optimized pharmacokinetics for solid tumor clearance.
Founders & Leadership
Dr. Jack HoppinCo-Founder & CEO
Dr. John BabichCo-Founder & CSO